CORT makes pipeline progress with the submission of a new drug application for relacorilant to treat patients with endogenous hypercortisolism.

CORT’s sole marketed drug, Korlym (mifepristone), is already approved for treating Cushing's syndrome. The drug has been witnessing a strong demand in the past couple of quarters and the trend ...

The drug has received orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome. Cushing's syndrome is a condition characterized by excessive ...

The drug has received orphan drug designation in the United States and the European Union for the treatment of Cushing's syndrome. Cushing's syndrome is a condition characterized by excessive cortisol ...

Corcept Therapeutics submitted a new drug application to the Food and Drug Administration for its treatment of hypercortisolism, or Cushing's syndrome, a hormonal disorder that occurs when the body ...